Endologix Inc. (ELGX) gapped open sharply lower Thursday morning and has continued to fall in early trade. The stock is now down 2.35 at $4.38 on above average volume. Endologix has dropped below support and has set a new low for the year.
Endologix announced Wednesday that, after a meeting with the FDA, it will conduct a confirmatory clinical study of its Nellix EVAS System. The company now estimates that PMA approval will occur in 2020.
by RTTNews Staff Writer
For comments and feedback: editorial@rttnews.com